Pegaspargase biosimilar - Pfenex

Drug Profile

Pegaspargase biosimilar - Pfenex

Alternative Names: PF690

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfenex
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Mar 2018 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA (IV, IM) (Jazz Pharmaceuticals pipeline, March 2018)
  • 28 Jul 2016 Pegaspargase licensed to Jazz Pharmaceuticals worldwide
  • 08 Sep 2014 Early research in Acute lymphoblastic leukaemia in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top